Short-term use of some NSAIDs could be dangerous to heart attack survivors

10 May 2011

Even short-term use of some painkillers could be dangerous for people who have had a heart attack, increasing their risk of a second attack and death, according to research published in Circulation, the Journal of the American Heart Association. The findings are similar to those posted on bmj.com (British Medical Journal) earlier this year (The Pharma Letter January 13).

Researchers in Denmark analyzed the duration of prescription non-steroidal anti-inflammatory drugs (NSAIDs) treatment and cardiovascular risk in a nationwide Danish cohort of patients with prior heart attack. They found the use of NSAIDs was associated with a 45% increased risk of death or recurrent heart attack within as little as one week of treatment, and a 55% increased risk if treatment extended to three months. The study was limited by its observational nature and the lack of clinical parameters, researchers said.

NSAIDs are commonly used by the general population and are associated with increased cardiovascular risk in people with heart disease or those at high risk. In a 2007 statement, the American Heart Association advised physicians about the risks of NSAID use among heart patients and provided a stepped care approach. In addition, the statement advised extra caution for when NSAIDs might be used, noting that they should "be limited to patients for whom there are not appropriate alternatives, and then, only in the lowest dose and for the shortest duration necessary."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical